Abstract
From February 1993 through July 1994, 37 patients with stage III-IV squamous cell carcinomas of the oral cavity, oropharynx, or hypopharynx (stage II-IV) were registered to a treatment regimen consisting of preoperative continuous infusion cisplatin (80 mg/m2/80 hours) with hyperfractionated external beam radiotherapy (9.1 Gy/7 fractions of 1.3 Gy BID), surgical resection, intraoperative radiotherapy (7.5 Gy), and postoperative radiotherapy (40 Gy) with concurrent cisplatin (100 mg/m2 x 2 courses). The objectives of the regimen were to improve patient compliance while also increasing treatment intensity. The purpose of this article is to report the local, regional (nodal), and distant disease control of these patients after an extended time at risk (median 40 months). Overall compliance (73%), local control at primary site (97%), and regional nodal control (95%) were excellent. The rate of distant metastasis was 19%. Absolute survival at 48 months was 45.9%.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / radiotherapy
-
Carcinoma, Squamous Cell / surgery*
-
Chemotherapy, Adjuvant / adverse effects
-
Cisplatin / therapeutic use*
-
Combined Modality Therapy / adverse effects
-
Dose Fractionation, Radiation
-
Follow-Up Studies
-
Head and Neck Neoplasms / drug therapy
-
Head and Neck Neoplasms / mortality
-
Head and Neck Neoplasms / radiotherapy
-
Head and Neck Neoplasms / surgery*
-
Humans
-
Hypopharyngeal Neoplasms / drug therapy
-
Hypopharyngeal Neoplasms / radiotherapy
-
Hypopharyngeal Neoplasms / surgery
-
Mouth Neoplasms / drug therapy
-
Mouth Neoplasms / radiotherapy
-
Mouth Neoplasms / surgery
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Oropharyngeal Neoplasms / drug therapy
-
Oropharyngeal Neoplasms / radiotherapy
-
Oropharyngeal Neoplasms / surgery
-
Patient Compliance
-
Radiotherapy Dosage
-
Survival Rate
-
Time Factors
-
Treatment Outcome